1. Prior malignancy<br/><br/>             • Note: Subjects who have had another malignancy and have been disease-free for 5<br/>             years, or subjects with a history of completely resected non-melanomatous skin<br/>             carcinoma or successfully treated in situ carcinoma are eligible.<br/><br/>          2. Patient has received prior treatment with any anti-angiogenic agent including<br/>             bevacizumab and tyrosine kinase inhibitors<br/><br/>          3. Active malignancy or any malignancy in the last 5 years prior to first dose of study<br/>             drug other than LMS and CS<br/><br/>          4. History or clinical evidence of central nervous system (CNS) or leptomeningeal<br/>             metastases, except for individuals who have previously-treated CNS metastases, are<br/>             asymptomatic, and have had no requirement for steroids or anti-seizure medication for<br/>             6 months prior to first dose of study drug. Screening with CNS imaging studies<br/>             (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if<br/>             clinically indicated or if the subject has a history of CNS metastases<br/><br/>          5. Clinically significant gastrointestinal abnormalities that may increase the risk for<br/>             gastrointestinal bleeding including, but not limited to:<br/><br/>               -  Active peptic ulcer disease<br/><br/>               -  Known intraluminal metastatic lesion/s with risk of bleeding<br/><br/>               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other<br/>                  gastrointestinal conditions with increased risk of perforation<br/><br/>               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal<br/>                  abscess within 28 days prior to beginning study treatment<br/><br/>               -  Grade 3/4 diarrhea<br/><br/>          6. Corrected QT interval (QTc) > 450 Milliseconds using Barzett's formula<br/><br/>          7. History of any one or more of the following cardiovascular conditions within the past<br/>             6 months:<br/><br/>               -  Cardiac angioplasty or stenting<br/><br/>               -  Myocardial infarction<br/><br/>               -  Unstable angina<br/><br/>               -  Coronary artery bypass graft surgery<br/><br/>               -  Symptomatic peripheral vascular disease<br/><br/>               -  Class III or IV congestive heart failure, as defined by the New York Heart<br/>                  Association (NYHA)<br/><br/>               -  Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥140<br/>                  mmHg or diastolic blood pressure (DBP) of ≥ 90 mmHg].<br/><br/>             Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior<br/>             to study entry. BP must be re-assessed on two occasions that are separated by a<br/>             minimum of 1 hour; on each of these occasions, the mean (of 3 readings) SBP / DBP<br/>             values from each BP assessment must be <140/90 mmHg in order for a subject to be<br/>             eligible for the study (refer to study protocol for details on BP control and<br/>             re-assessment prior to study enrollment)<br/><br/>          8. History of cerebrovascular accident including transient ischemic attack (TIA),<br/>             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6<br/>             months.<br/><br/>             • Note: Subjects with recent DVT who have been treated with therapeutic<br/>             anti-coagulating agents for at least 6 weeks are eligible<br/><br/>          9. Major surgery or trauma within 28 days prior to study enrolment or any non- healing<br/>             wound, fracture or ulcer (procedures such as catheter placement not considered to be<br/>             major)<br/><br/>         10. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs<br/>             chemically related to Pazopanib or Gemcitabine<br/><br/>         11. Evidence of active bleeding or bleeding diathesis<br/><br/>         12. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels<br/><br/>         13. Hemoptysis in excess of 2.5 mL(or one half teaspoon) within 8 weeks prior to the<br/>             first dose of study drug<br/><br/>         14. Any serious and/or unstable pre-existing medical, psychiatric, or other condition<br/>             that could interfere with subject's safety, provision of informed consent, or<br/>             compliance to study procedures<br/><br/>         15. Unable or unwilling to discontinue use of prohibited medications listed in the study<br/>             protocol for at least 14 days or five half-lives of a drug (whichever is longer)<br/>             prior to the first dose of study drug and for the duration of the study<br/><br/>         16. Treatment with any of the following anti-cancer therapies<br/><br/>               -  Radiation therapy, surgery or tumour embolization within 14 days prior to the<br/>                  first dose of study drug<br/><br/>               -  Chemotherapy, immunotherapy, biologic therapy, investigational therapy or<br/>                  hormonal therapy within 14 days or five half-lives of a drug (whichever is<br/>                  longer) prior to the first dose of study drug<br/><br/>         17. Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is<br/>             progressing in severity, except alopecia<br/><br/>         18. Pregnancy (for women of childbearing potential to be confirmed by negative serum<br/>             pregnancy test) or lactation period<br/><br/>             Women of childbearing potential:<br/><br/>             missing contraception (Pearl-Index <1, e.g. hormonal contraception including the<br/>             combined oral contraceptive pill, the transdermal patch, and the contraceptive<br/>             vaginal ring, intrauterine devices or sterilization) for 14 days before exposure to<br/>             investigational product, during study treatment and for at least 21 days after the<br/>             last dose of investigational product.<br/><br/>         19. Medical or psychological conditions that would not permit the subject to complete the<br/>             study or sign informed consent<br/><br/>         20. Legal incapacity or limited legal capacity<br/><br/>         21. Participation in another clinical study with experimental therapy within 30 days<br/>             prior to study enrolment<br/>